Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Concetta Conticello

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Frontiers in Oncology|March 25, 2021
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life SurveyUros Markovic, Alessandra Romano, Vittorio Del Fabro, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
Multiple Myeloma in 2023 Ways: From Trials to Real LifeManlio Fazio, Vittorio Del Fabro, Nunziatina Laura Parrinello, et al.
Haematologica|February 29, 2020
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studiesRoberto Mina, Francesca Bonello, Maria Teresa Petrucci, et al.
Cancer|December 19, 2018
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysisManuela Gambella, Paola Omedé, Stefano Spada, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 3, 2026
Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO StudyVittorio Montefusco, Anna Maria Cafro, Gloria Margiotta-Casaluci, et al.
Blood|May 24, 2014
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studySara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, et al.
Ejhaem|June 19, 2024
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in ItalyFrancesca Fazio, Maria Teresa Petrucci, Laura Corvatta, et al.
Stem Cell Research & Therapy|April 19, 2015
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party studyPellegrino Musto, Vittorio Simeon, Alberto Grossi, et al.
Oncogenesis|January 22, 2022
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironmentCesarina Giallongo, Ilaria Dulcamare, Daniele Tibullo, et al.
Oncotarget|October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Manuela Gambella, Milena Gilestro, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Frontiers in Oncology|March 25, 2021
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life SurveyUros Markovic, Alessandra Romano, Vittorio Del Fabro, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
Multiple Myeloma in 2023 Ways: From Trials to Real LifeManlio Fazio, Vittorio Del Fabro, Nunziatina Laura Parrinello, et al.
Haematologica|February 29, 2020
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studiesRoberto Mina, Francesca Bonello, Maria Teresa Petrucci, et al.
Cancer|December 19, 2018
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysisManuela Gambella, Paola Omedé, Stefano Spada, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 3, 2026
Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO StudyVittorio Montefusco, Anna Maria Cafro, Gloria Margiotta-Casaluci, et al.
Blood|May 24, 2014
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studySara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, et al.
Ejhaem|June 19, 2024
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in ItalyFrancesca Fazio, Maria Teresa Petrucci, Laura Corvatta, et al.
Stem Cell Research & Therapy|April 19, 2015
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party studyPellegrino Musto, Vittorio Simeon, Alberto Grossi, et al.
Oncogenesis|January 22, 2022
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironmentCesarina Giallongo, Ilaria Dulcamare, Daniele Tibullo, et al.
Oncotarget|October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Manuela Gambella, Milena Gilestro, et al.
Pageof 10